Oxurion completes enrollment of Phase I clinical trial evaluating THR-687 for DME
THR-687 (Pan RGD integrin antagonist)
THR-687, a pan RGD integrin antagonist, targets a broader spectrum of DR hallmarks. Preclinical models show that it is a potent inhibitor of angiogenesis-induced vascular leakage. The inhibition of integrins targets multiple processes involved in pathological angiogenesis and vascular leakage, unlike anti-VEGF treatment.
Oxurion has completed enrollment for a Phase I clinical trial to assess the safety of THR-687 in patients with DME.
Encouraging preclinical data presented at 20th annual EVER meeting highlight potential of
Phase I open-label, multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with DME
This Phase I study (THR-687-001 - NCT03666923) will primarily assess the safety of a single intravitreal injection of escalating dose levels of THR-687 in patients with DME. A total of 12 patients with DME have been enrolled into the US-based study (Clinicaltrials.gov: NCT03666923).
To be expected by the end of 2019
Preclinical studies have provided evidence that THR-687 is a potent and safe treatment, highlighting its ability to inhibit various significant stages in pathologic angiogenesis, a key factor leading to vision loss in diabetic eye disease. These preclinical data provide support for the clinical development of THR-687.